Enclomiphene for Fertility: What It Does, How It Compares to TRT, and Where to Get It (2026)

Executive Summary

Men researching testosterone treatment face a dilemma most don't anticipate: standard TRT suppresses sperm production. Exogenous testosterone signals the brain to halt LH and FSH secretion — the hormones that drive both testosterone production and spermatogenesis. For men who want to father children, this is a critical problem.

Enclomiphene offers a different path. As a selective estrogen receptor modulator (SERM), enclomiphene blocks estrogen's negative feedback at the hypothalamus and pituitary — causing the brain to release more LH and FSH, which in turn stimulates the testes to produce more testosterone. The result is higher testosterone through your own hormonal machinery, with sperm production preserved — and in many cases improved. This guide covers what the clinical evidence shows, who the right candidate is, how enclomiphene compares to TRT and to clomiphene (the older SERM it's derived from), what it costs, and how to access it in 2026. For the broader decision between enclomiphene and standard TRT, see our enclomiphene vs TRT comparison.

At-a-Glance Comparison

Comparison of enclomiphene vs TRT approaches for men with fertility concerns. TRT + HCG is included as a common fertility-preservation add-on to conventional TRT. Individual outcomes vary by protocol and provider.

What Enclomiphene Is and How It Works

Enclomiphene's mechanism is fundamentally different from TRT — understanding this difference is essential for making the right treatment choice when fertility matters. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Enclomiphene is the trans-isomer of clomiphene citrate (Clomid). Clomiphene has been used for male hypogonadism for decades, but it contains two isomers: enclomiphene (the active pro-gonadotropic isomer) and zuclomiphene (an estrogen-agonist with anti-gonadotropic effects that partially counteracts enclomiphene's benefit). Isolating enclomiphene removes the zuclomiphene burden, producing a cleaner pro-gonadotropic signal with fewer estrogen-related side effects. How it works: Enclomiphene blocks estrogen receptors at the hypothalamus and anterior pituitary. This prevents the negative feedback signal that estrogen normally sends to suppress gonadotropin release. With that inhibition lifted, the hypothalamus secretes more GnRH, the pituitary secretes more LH and FSH. LH signals the Leydig cells in the testes to produce more testosterone. FSH simultaneously supports Sertoli cell function and spermatogenesis. The result is that both testosterone and sperm production rise from endogenous stimulation — the opposite of what happens on TRT. This is why enclomiphene is specifically indicated for secondary hypogonadism (low testosterone caused by inadequate LH/FSH signaling from the hypothalamic-pituitary axis) rather than primary hypogonadism (where the testes themselves have failed and can't respond to LH stimulation). For background on this distinction, see our primary vs secondary hypogonadism guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: using enclomiphene for primary hypogonadism — where Leydig cells can't respond adequately to LH stimulation, enclomiphene will raise LH/FSH but testosterone won't respond meaningfully. Diagnosis matters before choosing this pathway. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

What the Clinical Evidence Shows

Enclomiphene has meaningful human clinical data behind it — including randomized controlled trials in secondary hypogonadism — though it remains an off-label treatment in most markets. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The clinical evidence for enclomiphene in secondary hypogonadism is solid, though the compound's regulatory history is complicated. Repros Therapeutics conducted multiple Phase II and Phase III trials of enclomiphene (branded as Androxal) targeting FDA approval for secondary hypogonadism. The trials demonstrated consistent findings: enclomiphene at 12.5–25mg/day raised serum testosterone to normal ranges in approximately 75–85% of men with secondary hypogonadism, typically within 4–8 weeks, while maintaining or improving sperm counts compared to topical TRT controls. Key trial data: in a Phase III trial comparing enclomiphene to testosterone gel, enclomiphene maintained sperm counts above 15 million/mL in the majority of subjects while achieving similar testosterone normalization. Testosterone gel suppressed sperm to near-zero in most subjects by 6 months. A 2026 British Society of Sexual Medicine position statement recognized enclomiphene as pro-gonadotropic and distinguished it from clomiphene's mixed-isomer profile, supporting its use in secondary hypogonadism where fertility preservation is a priority. LH and FSH both rise on enclomiphene — LH driving testosterone production, FSH driving spermatogenesis. This is the core clinical advantage over TRT for men in the family-planning window. Regulatory status: Enclomiphene did not receive FDA approval as a standalone branded drug (Androxal), primarily due to FDA requests for additional data after Phase III. It is now widely available as a compounded medication through telehealth platforms operating with prescribing physicians. The evidence base from the clinical trials is the same regardless of the regulatory status. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: confusing FDA non-approval with lack of efficacy — enclomiphene's off-label status reflects a regulatory pathway issue (compounding economics vs. new drug application costs), not a lack of clinical evidence. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Enclomiphene vs Clomiphene (Clomid): Why the Isomer Difference Matters

Clomiphene is commonly prescribed for male hypogonadism, but enclomiphene's isomeric purity gives it a cleaner clinical profile — understanding the difference matters if you're comparing options. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Clomiphene citrate (Clomid) contains approximately 62% zuclomiphene and 38% enclomiphene in its standard formulation. Enclomiphene is the pro-gonadotropic isomer — the one driving LH/FSH release and testosterone elevation. Zuclomiphene is partially estrogen-agonist, which means it partially counteracts enclomiphene's benefit and can accumulate in tissue (zuclomiphene has a longer half-life), contributing to the estrogen-related side effects some men experience on clomiphene: visual disturbances, mood changes, and estradiol elevation that can cause gynecomastia. Isolating enclomiphene addresses these issues: the pro-gonadotropic signal is cleaner, zuclomiphene accumulation is eliminated, and estrogen-mediated side effects are reduced compared to the mixed-isomer preparation. In head-to-head data, enclomiphene produces higher LH and FSH responses with a more favorable testosterone-to-estradiol ratio than clomiphene at equivalent doses. For men who have tried clomiphene and experienced mood or estrogen-related side effects, enclomiphene is a direct clinical upgrade. For men who tolerated clomiphene well, enclomiphene still tends to produce a cleaner hormonal response. The practical consideration: clomiphene is cheaper and more widely available (it's been generic for decades); enclomiphene requires compounding and costs more. If budget is the primary constraint and you have no side effect history with clomiphene, your physician may start you with clomiphene. If you want the cleanest pro-gonadotropic option or have had clomiphene side effects, enclomiphene is the better choice. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: assuming enclomiphene and clomiphene are equivalent because both are SERMs — the isomeric difference produces clinically meaningful differences in side effect profile and testosterone-to-estradiol ratio. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Who Is the Right Candidate for Enclomiphene

Enclomiphene is the right choice for a specific profile — and the wrong choice for others. Matching the tool to the clinical picture is what determines whether it works. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The ideal candidate for enclomiphene has three characteristics: confirmed secondary hypogonadism, an intact hypothalamic-pituitary-testicular (HPT) axis, and a reason to preserve fertility or natural testosterone production. More specifically, strong candidates include: men with symptomatic low testosterone + low-normal LH/FSH (the lab signature of secondary hypogonadism); men actively trying to conceive or planning to in the near term; men who want to raise testosterone without shutting down their HPT axis; men who prefer an oral treatment over injections or topicals; younger men (30s–40s) who may want to maintain the option to father children even if that's not an immediate priority. Poor candidates include: men with primary hypogonadism (testicular failure) — their LH is already high and enclomiphene will raise it further without meaningful testosterone response; men with a history of pituitary damage or pathology affecting GnRH/LH/FSH release — the axis needs to be functional for enclomiphene to work; men who have already undergone a vasectomy and have no fertility goals — they're better served by standard TRT with its more reliable and customizable hormone control; men with a history of SERM hypersensitivity. For men who are unsure whether secondary or primary hypogonadism applies to their case, the lab workup is straightforward: low testosterone with low-normal LH/FSH points to secondary; low testosterone with elevated LH/FSH points to primary. See our primary vs secondary hypogonadism guide for the full diagnostic picture. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: choosing enclomiphene without confirming hypogonadism type — men with primary hypogonadism will be disappointed with enclomiphene's testosterone response and should be on TRT instead. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Enclomiphene and Active Fertility Treatment

For men in active fertility treatment — either trying to conceive naturally or pursuing IUI/IVF — enclomiphene has a specific and well-supported role. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

When a man is actively trying to conceive, the goal is optimizing both testosterone and sperm parameters simultaneously. Enclomiphene directly addresses both by raising LH (→ testosterone) and FSH (→ spermatogenesis support). For men presenting to fertility workups with low testosterone and suboptimal sperm parameters, enclomiphene is often the first intervention recommended by reproductive endocrinologists before proceeding to more invasive approaches. Sperm parameter improvements on enclomiphene typically develop over 60–90 days — the time it takes for a complete spermatogenic cycle. Count, motility, and morphology improvements have all been documented in secondary hypogonadism patients. For men in assisted reproduction cycles (IUI or IVF with ICSI), optimizing sperm parameters before egg retrieval can improve fertilization rates — enclomiphene's FSH elevation directly supports this. Men on TRT who have suppressed sperm production and want to restore it for fertility purposes have two main options: discontinue TRT and switch to enclomiphene, or add HCG to TRT to stimulate testicular function. Enclomiphene alone is often the cleaner option for men who can accept the different testosterone control profile — it eliminates exogenous hormones entirely and restores the full natural axis. The timeline for sperm recovery after TRT depends on how long TRT was used and individual HPT axis resilience — most men recover meaningfully within 3–6 months, but recovery is not guaranteed in all cases. A reproductive endocrinologist should be involved when active IVF/IUI cycles are planned. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: assuming sperm recovery will be immediate after stopping TRT — HPT axis recovery after suppressive testosterone therapy takes months, and the process should start well before fertility treatment cycles are scheduled. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Dosing, Protocol Design, and Monitoring

Enclomiphene is a prescription medication that requires proper dosing and monitoring — here's what a well-run protocol looks like. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Standard enclomiphene dosing in clinical use: 12.5mg/day to 25mg/day oral, taken once daily. The Androxal Phase III trial used 12.5mg and 25mg doses; most telehealth protocols start at 12.5mg and titrate to 25mg if testosterone response is insufficient. Some protocols use 25mg five days on / two days off to reduce side effects or cost. Enclomiphene is taken orally — this is a meaningful advantage over injectable TRT for men who prefer not to inject. Monitoring protocol: baseline labs before starting (total testosterone, LH, FSH, estradiol, CBC, metabolic panel); 4–6 week follow-up labs (testosterone, LH, FSH, estradiol) to confirm response and check estradiol management; quarterly monitoring labs thereafter once stable. Estradiol monitoring matters because enclomiphene raises testosterone, and testosterone aromatizes to estradiol. Some men develop elevated estradiol requiring addition of a low-dose aromatase inhibitor (anastrozole 0.25–0.5mg twice weekly is common). Symptom tracking alongside labs: energy, libido, mood, and erection quality are the key metrics — these should be tracked at baseline and at 4–6 week intervals. A well-run protocol at a quality telehealth clinic will have these monitoring cadences built in. For clinic comparisons, see our best online enclomiphene clinics 2026. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: not monitoring estradiol — men with higher adiposity or more active aromatase can develop estradiol elevation on enclomiphene that offsets testosterone benefits and causes unwanted side effects. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

What Enclomiphene Costs in 2026 and How to Access It

Enclomiphene is available through telehealth platforms with a prescription — access is relatively straightforward and costs are manageable compared to many TRT protocols. Buyers searching for enclomiphene fertility usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Enclomiphene is a compounded medication in the US — not available as a branded drug, but prescribed off-label and dispensed through licensed compounding pharmacies. Access is primarily through telehealth platforms specializing in men's health and hormone optimization. Typical 2026 cost structure: $80–$200/month depending on provider platform and whether labs are bundled. Some platforms charge separately for consultation fees ($100–$200/intake), medication ($60–$120/month at the pharmacy), and lab draws ($75–$200 per panel). Others bundle these into monthly subscriptions. Compared to TRT, enclomiphene tends to be slightly cheaper overall — the oral delivery eliminates the supply and injection overhead, and the compounded medication is inexpensive. Compared to TRT + HCG (the main alternative for fertility preservation on exogenous testosterone), enclomiphene is typically less expensive. The platforms most commonly prescribing enclomiphene in 2026 include Defy Medical, Marek Health, and specialty men's health telehealth providers who understand secondary hypogonadism — not all budget TRT platforms are familiar with enclomiphene protocols. When evaluating a provider, ask: (1) Do you prescribe enclomiphene for secondary hypogonadism? (2) What is the monitoring protocol? (3) How is estradiol managed? (4) Can you add HCG if needed for fertility support? For a full comparison of enclomiphene providers, see our best online enclomiphene clinics 2026. For the broader provider landscape, see our provider comparison tool. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: using a budget TRT platform that isn't familiar with enclomiphene — some platforms only prescribe injectable TRT and lack the clinical depth to manage SERM-based protocols properly. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Enclomiphene requires a prescribing physician who understands secondary hypogonadism and SERM-based protocols — not all testosterone telehealth platforms offer it. The clinics below have experience with enclomiphene, including lab-based intake, estradiol monitoring, and fertility-preserving protocol design. Use our comparison tool to find the right fit.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does enclomiphene increase sperm count?

Yes — enclomiphene raises FSH, which directly supports Sertoli cell function and spermatogenesis. Clinical trials have documented maintained or improved sperm counts in men with secondary hypogonadism treated with enclomiphene, in contrast to testosterone gel which suppresses sperm production. Improvements in count, motility, and morphology typically develop over 60–90 days (one spermatogenic cycle).

Can I take enclomiphene instead of TRT?

For secondary hypogonadism — yes, in many cases. Enclomiphene raises testosterone through your own hormonal axis rather than replacing it with exogenous testosterone. For men with secondary hypogonadism who want to preserve fertility or avoid shutting down their natural axis, enclomiphene is often the better first-line option. For primary hypogonadism (testicular failure), enclomiphene won't produce adequate testosterone response and TRT is more appropriate.

How long does enclomiphene take to work?

Testosterone levels typically rise within 2–4 weeks of starting enclomiphene as LH and FSH increase. Subjective improvements in energy, libido, and mood usually follow at 4–8 weeks for responders. Sperm parameter improvements take longer — 60–90 days is the standard timeframe as the spermatogenic cycle completes.

Is enclomiphene FDA approved?

No — enclomiphene is not FDA approved as a standalone branded drug. The compound (branded as Androxal) completed Phase III trials for secondary hypogonadism but did not receive final FDA approval, primarily due to regulatory pathway economics rather than safety or efficacy issues. It is widely prescribed off-label and dispensed through licensed compounding pharmacies in the US.

What is the difference between enclomiphene and clomiphene (Clomid)?

Clomiphene contains two isomers — enclomiphene (pro-gonadotropic, the active component) and zuclomiphene (partially estrogen-agonist, partially counteracts enclomiphene's benefit). Enclomiphene in its pure form eliminates zuclomiphene, producing a cleaner pro-gonadotropic signal, a more favorable testosterone-to-estradiol ratio, and fewer estrogen-related side effects (mood changes, visual disturbances, gynecomastia risk). For men who tolerated clomiphene poorly, enclomiphene is a direct upgrade.

What are the side effects of enclomiphene?

Enclomiphene has a significantly cleaner side effect profile than clomiphene due to the absence of zuclomiphene. Common side effects are generally mild: some men experience headache, mild mood changes, or GI discomfort in the first few weeks. Estradiol elevation from increased testosterone aromatization can occur — this is managed with monitoring and low-dose anastrozole if needed. Serious side effects are rare at therapeutic doses. The visual disturbances seen with clomiphene are uncommon with enclomiphene.

Can I use enclomiphene if I'm already on TRT?

Men on TRT who want to transition to a fertility-preserving protocol can switch to enclomiphene — but it requires discontinuing exogenous testosterone and allowing the HPT axis to recover before enclomiphene becomes fully effective. Plan a 3–6 month transition period. Some men use HCG as a bridge during this period. Work with a physician who understands both protocols — the transition requires careful monitoring.

How much does enclomiphene cost?

Approximately $80–$200/month for the full protocol including medication and monitoring through a telehealth provider. The compounded medication itself runs $60–$120/month from most compounding pharmacies. Labs may be billed separately at $75–$200 per draw. Compared to TRT + HCG (the main alternative for men who want to preserve fertility on exogenous testosterone), enclomiphene tends to be slightly less expensive overall.

Who should NOT use enclomiphene?

Enclomiphene is not appropriate for: men with primary hypogonadism (testicular failure, high LH/FSH), men with pituitary pathology affecting GnRH/LH/FSH release, men with a history of SERM hypersensitivity, and men with certain hormonally sensitive conditions. The standard diagnostic prerequisite is confirming secondary hypogonadism via labs (low T + low-normal LH/FSH) before prescribing.

Where can I get enclomiphene prescribed online?

Enclomiphene is available through men's health telehealth platforms that specialize in hormone optimization — providers like Defy Medical, Marek Health, and specialized men's health clinics typically offer enclomiphene protocols. Not all budget TRT platforms prescribe it, so confirming SERM experience before signing up matters. See our best online enclomiphene clinics 2026 for a reviewed list.